OBJECTIVES: To assess and compare the impact of rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriasis (Ps) on work productivity, to estimate productivity costs in the Czech Republic and to evaluate the effect of functional status and disease activity on productivity costs. METHODS: According to Work Productivity and Activity Impairment Questionnaire was assessed productivity loss of patients with RA (n=77), AS (n=230), Ps (n=93) in productive age. Patient-reported outcome (PRO) (HAQ, BASDAI) and clinical parameters (DAS28, BSA, PASI) were also included. The interdependence among PROs and overall work productivity loss or productivity costs were described by Spearman´s rank correlation coefficient. Productivity costs were calculated by friction cost approach. RESULTS: Average patients age was 47.1 years (22-62) and average disease duration 15.7 years. Patients with RA revealed higher HAQ (1.22) compared to AS patients (1.00). Mean DAS28 of RA patients was 5.58 and mean BASDAI of AS patients was 4.43. Mean BSA and PASI for Ps patients were 21.09% and 12.85. The percentage of psoriatic arthritis (Ps patients) was 24.7%. We did not reported significant difference of WPAI among all diagnoses. Absenteeism for patients with RA, AS and Ps was 8.39%, 10.79% and 14.90%. Presenteeism was 40.26% for patients with RA, which was greater by 7.29% and 5.83% compared to AS and Ps patients. Patients with AS, RA and Ps reported overall work productivity loss of 40.85%, 42.92% and 42.82%, respectively. Activity impairments were approximately 50.00%. Average annual productivity costs per one patient with RA, AS and Ps were €1913, €1809 and €1908, respectively. Productivity costs strongly correlated with PROs, whereas correlations with clinical parameters were weak. CONCLUSIONS: The productivity loss was almost the same within all three diagnoses. HAQ, BASDAI in contrast to DAS28, BSA/PASI influenced productivity costs. Average annual productivity costs per each patient were almost €2000.